摘要
目的观察利拉鲁肽在2型糖尿病(type 2 diabetes mellitus,T2DM)合并急性ST段抬高型心肌梗死(ST-segment elevation myocardial infarction,STEMI)患者中的疗效。方法收集2016年10月—2018年5月收治的T2DM合并STEMI并行经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)者100例,随机分为试验组(n=50)和对照组(n=50),试验组加用利拉鲁肽降糖,对照组用降糖药物及(或)胰岛素降糖。比较两组术前、术后2 w、12 w的空腹血糖(fasting blood glucose,FBG)、糖化血红蛋白(glycosylated hemoglobin,HbA1c)、总胆固醇(total cholesterol,TC)、甘油三酯(triglyceride,TG)、低密度脂蛋白(low-density lipoprotein,LDL-C)、身体质量指数(body mass index,BMI)、左室射血分数(left ventricular ejection fraction,LVEF)、左心室舒张末期内径(left ventricular diastolic diameter,LVED)、舒张早期最大峰值速度/舒张晚期最大峰值速度(maximum diastolic velocity in early diastole/maximum diastolic peak velocity,E/A)。结果术后12 w试验组TC、TG、LDL-C、BMI、LVEF、LVED、E/A优于对照组(P <0.05)。结论 T2DM患者发生STEMI行PCI后加用利拉鲁肽可得到更多心血管获益。
Objective To observe the efficacy of liraglutide in patients with type 2 diabetes mellitus(T2DM)combined with acute ST-segment elevation myocardial infarction(STEMI).Methods 100 cases of patients with T2DM combined with STEMI who were given emergency percutaneous coronary intervention(PCI)from October 2016 to May 2018 were collected and randomly divided into experimental group(n=50)and control group(n=50).In the experimental group,liraglutide was used to control the blood glucose,while in the control group,hypoglycemic drugs and/or insulin were used.The fasting blood glucose(FBG),glycosylated hemoglobin(HbA1c),total cholesterol(TC),triglyceride(TG),low-density lipoprotein(LDL-C),body mass index(BMI),left ventricular ejection fraction(LVEF),left ventricular diastolic diameter(LVED),maximum diastolic velocity in early diastole/maximum diastolic peak velocity(E/A)were compared between the two group before operation,2 w and 12 w after operation.Results The TC,TG,LDL-C,BMI,LVEF,LVED and E/A in the experimental group were better than those the control group in 12 w after operation(P<0.05).Conclusion More cardiovascular benefits can be gained from the addition of liraglutide after STEMI giving PCI in patients with T2DM.
作者
岳晓燕
张大卫
YUE Xiaoyan;ZHANG Dawei(Department of Endocrinology,Rongcheng People's Hospital,Rongcheng Shandong 264300,China;Department of Cardiology,Rongcheng People's Hospital,Rongcheng Shandong 264300,China)
出处
《中国继续医学教育》
2018年第34期133-135,共3页
China Continuing Medical Education
